Impact of preexisting interstitial lung disease on outcomes of lung cancer surgery: A monocentric retrospective study.

Cancer ILD Lung NSCLC Surgery

Journal

Respiratory medicine and research
ISSN: 2590-0412
Titre abrégé: Respir Med Res
Pays: France
ID NLM: 101746324

Informations de publication

Date de publication:
30 Jul 2024
Historique:
received: 22 04 2024
revised: 17 06 2024
accepted: 03 07 2024
medline: 26 8 2024
pubmed: 26 8 2024
entrez: 25 8 2024
Statut: aheadofprint

Résumé

Interstitial lung disease (ILD) is a known risk factor for lung cancer (LC). However, the surgical risk of LC in patients with ILD remains unclear. Therefore, we conducted a single-center retrospective study to assess clinical features and outcomes of LC population who underwent surgery with or without ILD. Patients who underwent surgery for LC between January 2006 and June 2023 in our center were assessed using data extracted from the nationwide EPITHOR thoracic surgery database. Suspicion of ILD was based on patients' records. Confirmation of ILD was then made on the patient's medical and radiological history. Patients were classified according to the pattern of ILD. The study aimed to describe the outcomes after lung cancer resection in patients with confirmed LC-ILD group compared to those without ILD (LC-non-ILD): post-operative complications, disease-free survival (DFS) and overall survival (OS). A subgroup analysis was also performed on patients with idiopathic pulmonary fibrosis and lung cancer (LC-IPF). 4073 patients underwent surgery for LC at Assistance Publique des Hôpitaux de Marseille between January 2006 and June 2023. Of these, 4030 were in the LC-non-ILD group and 30 were LC-ILD patients. In the LC-ILD group, the predominant CT scan pattern was probable UIP (50 %). OS was not significantly lower in the LC-ILD group (45 months versus 84 months, p = 0.068). Dyspnea and tumor size were identified as potential univariate predictors of OS. No significant differences were observed on post-operative complications or their severity. The most common post-operative complications in the LC-ILD group were prolonged air leak, respiratory failure, or pneumonia. 13 patients had cancer recurrence in the LC-ILD group. Our study provides a comprehensive analysis of a LC-ILD population features and outcome when undergoing surgery for LC. Patients with LC-ILD appeared to have a reduced OS compared with LC-non-ILD. Further investigations with larger prospective studies could be useful to confirm and develop these preliminary findings.

Identifiants

pubmed: 39182360
pii: S2590-0412(24)00042-4
doi: 10.1016/j.resmer.2024.101126
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101126

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Alice Goga (A)

Service d'oncologie multidisciplinaires et innovations thérapeutiques, Département de Pneumologie, Hôpital Nord, AP-HM, Marseille, France; Aix Marseille Université, Marseille, France.

Alex Fourdrain (A)

Service de chirurgie thoracique, transplantations pulmonaires et maladies de l'œsophage, Hôpital Nord, AP-HM, Marseille, France; Aix Marseille Université, Marseille, France.

Paul Habert (P)

Service de Radiologie Hôpital Nord, AP-HM, Marseille, France; LIIE/UR 4264, Aix Marseille Université, Marseille, France; Aix Marseille Université, Marseille, France.

Anh Thu Nguyen Ngoc (AT)

CEReSS/UR 3279 Centre d'étude et de recherche sur les services de santé et la qualité de vie, Aix Marseille Université Marseille France, France; Service de Support méthodologique pour les recherche clinique et épidémiologique, AP-HM, Marseille France.

Julien Bermudez (J)

Service des maladies respiratoires rares, mucoviscidose, transplantation, Département de Pneumologie, Hôpital Nord, AP-HM, Marseille, France; Aix Marseille Université, Marseille, France.

Alice Mogenet (A)

Service d'oncologie multidisciplinaires et innovations thérapeutiques, Département de Pneumologie, Hôpital Nord, AP-HM, Marseille, France; Aix Marseille Université, Marseille, France.

Eléonore Simon (E)

Service d'oncologie multidisciplinaires et innovations thérapeutiques, Département de Pneumologie, Hôpital Nord, AP-HM, Marseille, France; Aix Marseille Université, Marseille, France.

Etienne Gouton (E)

Service d'oncologie multidisciplinaires et innovations thérapeutiques, Département de Pneumologie, Hôpital Nord, AP-HM, Marseille, France; Aix Marseille Université, Marseille, France.

Pascale Tomasini (P)

Service d'oncologie multidisciplinaires et innovations thérapeutiques, Département de Pneumologie, Hôpital Nord, AP-HM, Marseille, France; Aix Marseille Université, Marseille, France; Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France; INSERM, France; CNRS, France.

Pascal Alexandre Thomas (PA)

Service de chirurgie thoracique, transplantations pulmonaires et maladies de l'œsophage, Hôpital Nord, AP-HM, Marseille, France; Aix Marseille Université, Marseille, France.

Laurent Greillier (L)

Service d'oncologie multidisciplinaires et innovations thérapeutiques, Département de Pneumologie, Hôpital Nord, AP-HM, Marseille, France; Aix Marseille Université, Marseille, France; Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France; INSERM, France; CNRS, France.

Johan Pluvy (J)

Service d'oncologie multidisciplinaires et innovations thérapeutiques, Département de Pneumologie, Hôpital Nord, AP-HM, Marseille, France. Electronic address: johan.pluvy@ap-hm.fr.

Classifications MeSH